Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Gary Cutter

Showing results (281-290 of 333) with videos related to

Pageof 34
Sort By:
Journal of Neurology|November 6, 2021
The impact of the COVID-19 pandemic on an international rehabilitation study in MS: the CogEx experienceAnthony Feinstein, Maria Pia Amato, Giampaolo Brichetto, et al.
Journal of Neurology|August 20, 2020
The emotional impact of the COVID-19 pandemic on individuals with progressive multiple sclerosisNancy D Chiaravalloti, Maria Pia Amato, Giampaolo Brichetto, et al.
The Lancet. Neurology|November 19, 2020
COVID-19-associated risks and effects in myasthenia gravis (CARE-MG)Srikanth Muppidi, Jeffrey T Guptill, Saiju Jacob, et al.
Journal of Neurology|August 8, 2022
The late onset of emotional distress in people with progressive multiple sclerosis during the Covid-19 pandemic: longitudinal findings from the CogEx studyAnthony Feinstein, Maria Pia Amato, Giampaolo Brichetto, et al.
The Lancet. Neurology|September 22, 2023
Cognitive rehabilitation and aerobic exercise for cognitive impairment in people with progressive multiple sclerosis (CogEx): a randomised, blinded, sham-controlled trialAnthony Feinstein, Maria Pia Amato, Giampaolo Brichetto, et al.
Multiple Sclerosis (Houndmills, Basingstoke, England)|December 16, 2015
Placebo-controlled study in neuromyelitis optica-Ethical and design considerationsBruce Ac Cree, Jeffrey L Bennett, Mark Sheehan, et al.
Neurology|June 25, 2003
A randomized controlled study of the acute and chronic effects of cooling therapy for MSSteven R Schwid, Mary D Petrie, Ronald Murray, et al.
Arthritis & Rheumatology (Hoboken, N.J.)|March 22, 2021
Reducing Immunogenicity of Pegloticase With Concomitant Use of Mycophenolate Mofetil in Patients With Refractory Gout: A Phase II, Randomized, Double-Blind, Placebo-Controlled TrialPuja P Khanna, Dinesh Khanna, Gary Cutter, et al.
Multiple Sclerosis Journal - Experimental, Translational and Clinical|December 9, 2024
Heterogeneity of aerobic fitness changes with exercise training in progressive multiple sclerosis: Secondary, exploratory analysis of data from the CogEx trialRobert W Motl, Brian M Sandroff, Roberto S Hernandez, et al.
Journal of Neurology, Neurosurgery, and Psychiatry|May 23, 2023
Serum neurofilament light chain levels at attack predict post-attack disability worsening and are mitigated by inebilizumab: analysis of four potential biomarkers in neuromyelitis optica spectrum disorderOrhan Aktas, Hans-Peter Hartung, Michael A Smith, et al.
Pageof 34

Showing results (281-290 of 333) with videos related to

Sort By:
Pageof 34
Journal of Neurology|November 6, 2021
The impact of the COVID-19 pandemic on an international rehabilitation study in MS: the CogEx experienceAnthony Feinstein, Maria Pia Amato, Giampaolo Brichetto, et al.
Journal of Neurology|August 20, 2020
The emotional impact of the COVID-19 pandemic on individuals with progressive multiple sclerosisNancy D Chiaravalloti, Maria Pia Amato, Giampaolo Brichetto, et al.
The Lancet. Neurology|November 19, 2020
COVID-19-associated risks and effects in myasthenia gravis (CARE-MG)Srikanth Muppidi, Jeffrey T Guptill, Saiju Jacob, et al.
Journal of Neurology|August 8, 2022
The late onset of emotional distress in people with progressive multiple sclerosis during the Covid-19 pandemic: longitudinal findings from the CogEx studyAnthony Feinstein, Maria Pia Amato, Giampaolo Brichetto, et al.
The Lancet. Neurology|September 22, 2023
Cognitive rehabilitation and aerobic exercise for cognitive impairment in people with progressive multiple sclerosis (CogEx): a randomised, blinded, sham-controlled trialAnthony Feinstein, Maria Pia Amato, Giampaolo Brichetto, et al.
Multiple Sclerosis (Houndmills, Basingstoke, England)|December 16, 2015
Placebo-controlled study in neuromyelitis optica-Ethical and design considerationsBruce Ac Cree, Jeffrey L Bennett, Mark Sheehan, et al.
Neurology|June 25, 2003
A randomized controlled study of the acute and chronic effects of cooling therapy for MSSteven R Schwid, Mary D Petrie, Ronald Murray, et al.
Arthritis & Rheumatology (Hoboken, N.J.)|March 22, 2021
Reducing Immunogenicity of Pegloticase With Concomitant Use of Mycophenolate Mofetil in Patients With Refractory Gout: A Phase II, Randomized, Double-Blind, Placebo-Controlled TrialPuja P Khanna, Dinesh Khanna, Gary Cutter, et al.
Multiple Sclerosis Journal - Experimental, Translational and Clinical|December 9, 2024
Heterogeneity of aerobic fitness changes with exercise training in progressive multiple sclerosis: Secondary, exploratory analysis of data from the CogEx trialRobert W Motl, Brian M Sandroff, Roberto S Hernandez, et al.
Journal of Neurology, Neurosurgery, and Psychiatry|May 23, 2023
Serum neurofilament light chain levels at attack predict post-attack disability worsening and are mitigated by inebilizumab: analysis of four potential biomarkers in neuromyelitis optica spectrum disorderOrhan Aktas, Hans-Peter Hartung, Michael A Smith, et al.
Pageof 34